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bronchial anastomosis in terms of late com-
plications. Finally, the completeness of re-
section after lung-sparing resection in term
of extension of mediastinal and hilar lymph
node dissection was comparable to that ob-
tained after pneumonectomy. At present,
our experience with lung-sparing technique
for lung cancer after induction treatment
consists of 58 patients operated on through
a period of 5 years, and it represent 54% of
all sleeve resections performed during the
same period (n  106). A vascular resec-
tion was associated in 35% of cases. The
overall postoperative morbidity rate and
mortality of patients who underwent sleeve
resection were 34% and 4.7%, respec-
tively. Table 1 reports the comparison be-
tween the two groups (induction treatment
vs no treatment).
This recent updated experience con-
firms our previous results and strongly sup-
ports the result of the article of Ohta and
colleagues.1 Bronchoplastic resection after
induction chemotherapy is a safe treatment
for locally advanced lung cancer, and it
should be done whenever it is possible in-
stead of pneumonectomy.
G. Veronesi, MD
M. E. Leon
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Reply to the Editor:
My coauthors and I appreciate the com-
ments by Veronesi and colleagues from the
European Institute of Oncology. We find
their results1 to be consistent with ours,2
with their latest study reconfirming our
conclusion. They had excellent outcomes
with a sleeve resection after induction ther-
apy; however, the overall morbidity and
mortality resulting from a primary opera-
tion were 44% and 6%, respectively, which
were higher than those of Kutlu and Gold-
straw3 (12% and 2%, respectively), who
used the same continuous suture technique
for the bronchial anastomosis as did Vero-
nesi and colleagues.1 The somewhat high
morbidity rate in their control group may
have had an influence on the statistical
comparison analysis. Because surgical
complications had a correlation with the
extent of surgical resections,4 patients in
their study who underwent a primary oper-
ation have probably received a more radi-
cal dissection of the tumor and invaded
organs.
In our experience to date, the overall
surgical morbidity of 22 patients who re-
ceived preoperative induction therapy is
32% and that of 38 patients who underwent
a primary operation is 8%, and no postop-
erative deaths have occurred. Thus we be-
lieve that a sleeve resection is useful for
any patient with centrally located advanced
lung cancer in whom the anatomy is suit-
able for such a procedure. Further, we can
insist, and are supported by the results of
Veronesi and colleagues,2 that a sleeve re-
section is a safe alternative to pneumonec-
tomy, irrespective of preoperative treat-
ment.
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Lack of evidence for vitamin C as
acute vasodilator
To the Editor:
We read with interest the article by Drossos
and colleagues.1 They measured radial ar-
tery diameter before and after acute oral
administration of vitamin C (2 g) in two
separate studies. Study one was a compar-
ison in healthy subjects comparing non-
smokers with smokers; study two was dou-
ble-blind comparison with diltiazem.
The article raises several issues that we
believe require clarification by the authors.
First, the article does not contain any data
on the diameter measurements. This is im-
portant, because previous studies2,3 that
TABLE 1. Comparison of postoperative morbidity and mortality in patients un-
dergoing bronchial sleeve resection (induction treatment versus no treatment)
Overall
(n  106)
Induction
(n  56)
No induction
(n  50)
P valueNo. % No. % No. %
Perioperative morbidity
Minor complications 29 27.5 12 21.4 17 34 .15
Major complications 7 6.6 5 8.9 2 4 .44
Late morbidity 6 5.6 3 5.3 3 6 .99
Perioperative mortality 5 4.7 2 3.6 3 6 .66
Letters to the Editor
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 5 1671
